05:26 PM EST, 11/25/2024 (MT Newswires) -- Enanta Pharmaceuticals ( ENTA ) late Monday reported a fiscal Q4 net loss of $1.36 per diluted share, compared with $1.33 loss a year earlier.

Analysts surveyed by FactSet expected a loss of $1.16.

Revenue for the quarter ended Sept. 30 declined to $14.6 million from $18.9 million a year earlier. Analysts polled by FactSet expected $18 million.

The company said its funds will be sufficient to meet the anticipated cash requirements of its existing business and development programs into fiscal 2027.